Australia's most trusted
source of pharma news
Wednesday, 18 June 2025
Posted 10 June 2025 PM
AstraZeneca has launched new economic modelling showing the government could secure up to $1.6 billion in lost taxes if chronic kidney disease (CKD) is raised to a public health priority.
The company says the modelling shows that improved diagnosis and treatment of the condition over a 25-year period could keep 200,000 more people working and paying tax as well as saving $25.2 billion in CKD-related costs.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.